Biotech | July 10, 2022
WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Site Enhances New Modality CRDMO Platform Capacity for Customers
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
Medicfibers in collaboration with AIIMS New Delhi, has developed an antimicrobial solution Viroclog that when applied as a coating on textiles, provides long-lasting protection against HAI by reducing virus, bacteria, fungi survival on fabric
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Subscribe To Our Newsletter & Stay Updated
